Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2022-08-21 Major Shareholding Noti…
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Ceasing to be a substantial holder 3 pages 128.6KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 notice under the Corporations Act 2001 Section 671B, which is a statutory disclosure of ceasing to be a substantial holder in a company. It details changes in relevant interests, share disposals, and associations related to substantial shareholdings. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category Major Shareholding Notification (MRQ). The document is not a financial report, earnings release, or management report, but a regulatory disclosure about shareholding changes.
2022-08-21 English
Long COVID study identifies diagnostic & therapeutic targets 3 pages 190.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 19 August 2022 from Antisense Therapeutics Limited. It details the outcomes of a scientific collaboration studying Long COVID-19, including novel blood markers identified as potential diagnostic and therapeutic targets. The announcement discusses provisional patent filings, scientific study results, and plans for further research and commercial discussions. There are no financial statements, earnings data, or regulatory certifications present. The document is a corporate announcement about research progress and intellectual property, not a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information rather than just announcing a report release. Therefore, the document fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous corporate announcements that do not fit other specific categories.
2022-08-18 English
Long Covid-19 Collaboration Outcomes Presentation 28 pages 1.7MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation focused on scientific and medical research findings related to proteomics analysis in Long COVID-19 patients. It includes extensive data analysis, statistical tests, and results interpretation. The content is technical and research-oriented, with no indication of financial results, regulatory filings, management changes, or shareholder information. The document is structured as a presentation with disclaimers and references to studies, typical of an Investor Presentation or scientific presentation to stakeholders. There is no indication that this is an Annual Report, Earnings Release, or any regulatory filing. The length (15,000 characters) and detailed content support it being a full presentation rather than a brief announcement or summary. Therefore, the most appropriate classification is Investor Presentation (IP).
2022-08-18 English
Response to ASX Query 6 pages 243.9KB
Regulatory Filings Classification · 95% confidence The document is a letter from Antisense Therapeutics Limited responding to a query from ASX Compliance regarding a recent trading halt and voluntary suspension related to the company's announcement about Long COVID-19 study outcomes and patent applications. The letter addresses specific questions from ASX about the status of data, patent applications, compliance with listing rules, and approval of disclosures. It is a regulatory correspondence focused on compliance and disclosure matters rather than a financial report, earnings release, or presentation. The document is not a report itself but a response to a regulatory inquiry, fitting the category of a Regulatory Filing (RNS). The length and content confirm it is not a brief announcement or a full financial report but a detailed regulatory response.
2022-08-18 English
Reinstatement to Official Quotation 1 page 89.8KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from ASX regarding the reinstatement to quotation of Antisense Therapeutics Limited's securities. It is a brief notice about lifting a trading suspension, not a financial report or detailed filing. The document length is short (687 characters), and it serves as an official regulatory announcement about trading status rather than financial results, management changes, or other report types. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for general regulatory announcements that do not fit other specific categories.
2022-08-18 English
Voluntary Suspension 2 pages 171.9KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Antisense Therapeutics Limited regarding the immediate suspension of its securities from quotation on the ASX, citing Listing Rule 17.2. It is a formal request for voluntary suspension of trading, not a financial report or detailed disclosure of financial results. The document is short (1854 characters) and serves as an official notice about trading suspension rather than a report or detailed filing. This fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2022-08-16 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.